ArticleThe oncologist2025
Global variations in oncology professionals' confidence levels for managing antibody-drug conjugate toxicities: a cross-continental survey.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAntibody-drug conjugates (ADCs) represent a promising therapeutic approach in oncology, but managing their toxicities remains challenging. This survey aimed to assess confidence levels in ADC toxicity management among oncology professionals globally.
methodsA cross-sectional survey was conducted using the ONCOassist mobile, a CE-marked oncology application widely used by oncologists globally as support in clinical practice. Confidence in toxicity management was measured on a 5-point scale. Predictor variables included income level, professional role, specialization, and cancer type treated.
resultsThe survey was offered to 5883 users, and responses were received from 1256 oncology healthcare professionals (HCPs) across various continents and professional roles. Medical oncologists represented the largest group (46%). Most of the HCPs were from high- or upper-middle-income countries (75%) with most nurses (86%) from high-income countries. Respondents from Europe and North America reported higher confidence ratings, while those from Asia, Africa, and Oceania tended to report lower confidence levels (P < .001). Respondents from lower-middle-income countries reported lower confidence compared with those from high- and upper-middle-income countries (P < .001). Additionally, senior physicians exhibited substantially higher confidence compared to junior physicians and nurse practitioners (P < .001, for both). Specialty affected confidence levels, particularly in surgical oncologists who reported the lowest confidence (P < .001).
conclusionThis global survey reveals significant disparities in confidence levels for managing ADC toxicities across regions, professional roles, and specializations. These findings may suggest the need for targeted educational interventions and support systems to enhance competences in managing ADC-related toxicities, ultimately improving the global standard of care for patients receiving ADCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.